Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of MK-1293 vs Lantus in Type 1 Diabetes
NCT02059174Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2014
- Primary completion
- Mar 2015
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 1, randomised, triple-blind trial of lusduna nexvue in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Merck & Co. Primary endpoints: Duration of Pharmacodynamic Action at 30 hours, Area Under the Glucose Infusion Rate Curve 0-24h and 5 more. Started Feb 2014; status: completed.
02
Drugs
lusduna nexvue
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT02059174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02059174.